Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADX:JULPHAR's PB Ratio is ranked worse than 58.04% of 112
companies
in the Medical Distribution industry
Industry Median: 1.055
vs ADX:JULPHAR: 1.25
During the past 12 months, Gulf Pharmaceutical Industries PSC's average Book Value Per Share Growth Rate was 4.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -1.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -15.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Gulf Pharmaceutical Industries PSC was 131.60% per year. The lowest was -34.80% per year. And the median was -2.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Gulf Pharmaceutical Industries PSC PB Ratio Related Terms
Gulf Pharmaceutical Industries PSC PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's PB Ratio distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's PB Ratio falls into.
Gulf Pharmaceutical Industries PSC PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a PB Ratio of 1.24 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. This is 13% below median its historical median of 1.42. Over the past decade, Gulf Pharmaceutical Industries PSC's PB Ratio has ranged from 0.75 to 2.49. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #65 out of 112 companies in the Medical Distribution industry, placing it in the top 58%.
Is Gulf Pharmaceutical Industries PSC's PB Ratio too high?
Gulf Pharmaceutical Industries PSC's current PB Ratio of 1.24 is 13% below median its 10-year median of 1.42. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 2.49. The Medical Distribution industry median PB Ratio is 1.06. Gulf Pharmaceutical Industries PSC's value of 1.24 is 17.5% above this industry median. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #65 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #65 out of 112 companies for PB Ratio. This places Gulf Pharmaceutical Industries PSC in the lower half of its industry. The industry median PB Ratio is 1.06. Gulf Pharmaceutical Industries PSC's value of 1.24 is 17.5% above this benchmark. Historically, Gulf Pharmaceutical Industries PSC's own PB Ratio has ranged from 0.75 to 2.49 over the past decade. While the company's 10-year median is 1.42 vs. the industry median of 1.06, Gulf Pharmaceutical Industries PSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.06, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gulf Pharmaceutical Industries PSC's current PB Ratio of 1.24 is 17.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gulf Pharmaceutical Industries PSC's current PB Ratio is 1.24, which is 13% below median its own 10-year median of 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.08, compared to a current price of د.إ1.05 — trading 2.8% below its estimated fair value. The current PB Ratio is 1.24, which is 13% below median its 10-year median of 1.42 and 17.5% above the Medical Distribution industry median of 1.06. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current PB Ratio is 1.24 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.05 is trading 2.8% below its estimated GF Value™ of د.إ1.08.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
PB Ratio: 1.24 (13% below median its 10-year median of 1.42)
GF Value™: د.إ1.08 vs. price of د.إ1.05 (2.8% below fair value)
Industry Position: 17.5% above the Medical Distribution median (#65 of 112)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score
Get the complete analysis for ADX:JULPHAR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
